This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Herman, T. S. Articles by Jones, S. M. Search for Related Content PubMed PubMed Citation Articles by Herman, T. S. Articles by Jones, S. M.

Addition of 2-Nitroimidazole Radiosensitizers to cis-Diamminedichloroplatinum(II) with Radiation and with or without Hyperthermia in the Murine FSaIIC Fibrosarcoma¹

Dana-Farber Cancer Institute [T. S. H., B. A. T., S. A. H., M. R. P., S. M. J.] and Joint Center for Radiation Therapy [T. S. H., M. R. P], Boston, Massachusetts 02115

We have examined the ability of misonidazole (MISO) or etanidazole (ETA) to improve the antitumor efficacy of cisplatin (CDDP), hyperthermia, and radiation in the FSaIIC murine fibrosarcoma. A growth delay of about 25 days was produced with CDDP (5 mg/kg) and hyperthermia (43°C, 30 min) prior to radiation (3 Gy daily for 5 days) on day 1. The addition of MISO (1 g/kg) on day 1 resulted in a tumor growth delay of about 28 days. The addition of ETA at 0.5 g/kg or 1 g/kg resulted in tumor growth delays of about 33 and 43 days, respectively. Tumor cell survival assay showed that MISO was additive with CDDP either at 37°C or with hyperthermia (43°C, 30 min). In contrast, ETA at both 0.5 g/kg and 1 g/kg was dose modifying over the CDDP dosage range at 37°C or 43°C. Analysis of tumor cell killing in Hoechst 33342 selected bright (presumably oxic) and dim (presumably hypoxic) tumor cell subpopulations demonstrated that the addition of MISO to the CDDP trimodality regimen increased killing in the dim cell subpopulation, while the addition of ETA increased tumor cell killing in both subpopulations, although the greater effect was in the dim cell subpopulation. These results indicate that ETA may add to the efficacy of the CDDP trimodality in the clinic and may be of value as a chemosensitizer with CDDP.

¹ This work was supported by National Cancer Institute grants RO1-CA36508 and RO1-CA47379 and a grant from Bristol-Myers Corporation.

² To whom requests for reprints should be addressed, at Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115.

Received 7/20/89. Revised 12/19/89.

This article has been cited by other articles:

				T Wakasa, N Kawai, Y Yanagi, Y Hayase, and K Kishi A study of hypoxic cell radiosensitizer applied to Ehrlich ascite tumour: a comparison of FC43 emulsion and pentoxyfilline Br. J. Radiol., November 1, 2002; 75(899): 909 - 912. [Abstract] [Full Text] [PDF]